Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
Open Access
- 4 May 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (17), 1784-1786
- https://doi.org/10.1001/jama.2021.4385
Abstract
Immunocompromised individuals have been excluded from studies of SARS-CoV-2 messenger RNA (mRNA) vaccines. In such patients, the immune response to vaccination may be blunted. To better understand the immunogenicity of mRNA vaccines in immunocompromised individuals, we quantified the humoral response to the first dose in solid organ transplant recipients.Keywords
This publication has 6 references indexed in Scilit:
- Early Development and Durability of SARS-CoV-2 Antibodies Among Solid Organ Transplant Recipients: A Pilot StudyTransplantation, 2021
- Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical EvaluationJournal of Clinical Microbiology, 2021
- Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing TitersJournal of Clinical Microbiology, 2021
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesThe New England Journal of Medicine, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportThe New England Journal of Medicine, 2020
- Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor populationJCI Insight, 2020